These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12918127)

  • 1. p53 protein expression and CA19.9 values in differential cytological diagnosis of pancreatic cancer complicated with chronic pancreatitis and chronic pancreatitis.
    Mu DQ; Wang GF; Peng SY
    World J Gastroenterol; 2003 Aug; 9(8):1815-8. PubMed ID: 12918127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
    Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
    Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The assessment of serum and diagnostic peritoneal lavage concentration of matrix metalloproteinase-2, matrix metalloproteinase-9, carbohydrate antigen 19-9, and carcinoembryonic antigen in patients with pancreatic cancer and chronic pancreatitis.
    Dranka-Bojarowska D; Lewinski A; Lekstan A; Gajda M; Ciosek J; Mrowiec S
    J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
    Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
    JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.
    Su SB; Qin SY; Chen W; Luo W; Jiang HX
    World J Gastroenterol; 2015 Apr; 21(14):4323-33. PubMed ID: 25892884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2016 Mar; 16(4):537-43. PubMed ID: 27002756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of p53 protein during pancreatitis.
    Maacke H; Kessler A; Schmiegel W; Roeder C; Vogel I; Deppert W; Kalthoff H
    Br J Cancer; 1997; 75(10):1501-4. PubMed ID: 9166944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
    Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
    Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.
    Kuhlmann KF; van Till JW; Boermeester MA; de Reuver PR; Tzvetanova ID; Offerhaus GJ; Ten Kate FJ; Busch OR; van Gulik TM; Gouma DJ; Crawford HC
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):886-91. PubMed ID: 17507610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection.
    Fahrmann JF; Schmidt CM; Mao X; Irajizad E; Loftus M; Zhang J; Patel N; Vykoukal J; Dennison JB; Long JP; Do KA; Zhang J; Chabot JA; Kluger MD; Kastrinos F; Brais L; Babic A; Jajoo K; Lee LS; Clancy TE; Ng K; Bullock A; Genkinger J; Yip-Schneider MT; Maitra A; Wolpin BM; Hanash S
    Gastroenterology; 2021 Mar; 160(4):1373-1383.e6. PubMed ID: 33333055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease.
    Ritts RE; Nagorney DM; Jacobsen DJ; Talbot RW; Zurawski VR
    Pancreas; 1994 Nov; 9(6):707-16. PubMed ID: 7846013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
    Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
    Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
    Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentration of D-dimers in Bile-a Novel Marker of Pancreatic Cancer Enhancing Accuracy of Standard CA19-9 Measurement: Dual Test Hypothesis.
    Durczynski A; Kumor A; Grzelak P; Strzelczyk M; Hogendorf P; Poznanska G; Skulimowski A; Szymanski D; Strzelczyk J
    Pancreas; 2017 Jan; 46(1):e9-e10. PubMed ID: 27763956
    [No Abstract]   [Full Text] [Related]  

  • 16. Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer.
    Jiang JT; Wu CP; Deng HF; Lu MY; Wu J; Zhang HY; Sun WH; Ji M
    World J Gastroenterol; 2004 Jun; 10(11):1675-7. PubMed ID: 15162550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of miR-16 plus CA19-9 detections on pancreatic cancer diagnostic performance.
    Gao L; He SB; Li DC
    Clin Lab; 2014; 60(1):73-7. PubMed ID: 24600978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
    Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A
    Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis of pancreatic cancer using ¹⁸F-FDG PET/CT and CA19-9 with SUVmax association to clinical characteristics.
    Sun Y; Duan Q; Wang S; Zeng Y; Wu R
    J BUON; 2015; 20(2):452-9. PubMed ID: 26011335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.
    Salek C; Benesova L; Zavoral M; Nosek V; Kasperova L; Ryska M; Strnad R; Traboulsi E; Minarik M
    World J Gastroenterol; 2007 Jul; 13(27):3714-20. PubMed ID: 17659731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.